Fulgent Genetics, Inc. FLGT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Laboratory Services | $319.81M-0.7% | $322.22M+2.2% | $315.41M+4.0% | $303.22M+3.7% | $292.45M+3.2% | |
| Therapeutic Development | $534K+19.5% | $447K+224% | $138K— | $0— | $0— | |
| Operating Income by Business | ||||||
| Laboratory Services | -$19.72M-163% | -$7.51M— | —— | —— | —— | |
| Therapeutic Development | -$20.05M-1.0% | -$19.85M-1.4% | -$19.57M-12.6% | -$17.39M-0.8% | -$17.25M-4.1% | |
| Cost Of Revenue by Business | ||||||
| Laboratory Services | $189.81M+2.6% | $184.96M+3.7% | $178.34M+2.2% | $174.51M+1.8% | $171.42M+1.8% | |
| Therapeutic Development | $13K+160% | $5K— | $0— | $0— | $0— | |
| Interest Expense Nonoperating by Business | ||||||
| Laboratory Services | $78K+4.0% | $75K— | —— | —— | —— | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Finite Lived Intangible Assets Gross by Business | ||||||
| Laboratory Services | $354.51M+6.6% | $332.45M0.0% | $332.41M0.0% | $332.42M0.0% | $332.41M0.0% | |
| Finite Lived Intangible Assets Net by Business | ||||||
| Laboratory Services | $276.82M+5.7% | $261.94M-2.9% | $269.77M-2.9% | $277.8M-2.8% | $285.72M-2.7% | |
| Selling And Marketing Expense by Business | ||||||
| Laboratory Services | $44.35M+9.9% | $40.35M+4.3% | $38.67M+7.5% | $35.96M+12.5% | $31.98M-1.1% | |
| Therapeutic Development | $5K0.0% | $5K— | $0— | $0— | $0— | |
| Total Assets by Business | ||||||
| Laboratory Services | $4.34B-1.6% | $4.41B-0.8% | $4.44B-1.4% | $4.5B-0.7% | $4.54B-0.5% | |
| Therapeutic Development | $446.08M+4.8% | $425.85M+7.1% | $397.55M+12.1% | $354.7M0.0% | $354.75M-0.1% | |
| Investment Income Interest by Business | ||||||
| Laboratory Services | $31.55M+2.0% | $30.92M-3.7% | $32.11M-0.7% | $32.32M+1.2% | $31.94M+2.0% | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | ||||||
| Laboratory Services | $23.17M+7.1% | $21.64M+7.8% | $20.07M+2.8% | $19.52M+3.0% | $18.94M+4.0% | |
| Therapeutic Development | $19.23M+1.0% | $19.04M+4.0% | $18.31M+11.3% | $16.45M+1.3% | $16.23M+3.8% | |
| General And Administrative Expense by Business | ||||||
| Laboratory Services | $82.21M-0.7% | $82.78M+2.3% | $80.95M+2.9% | $78.69M+7.4% | $73.3M+5.7% | |
| Therapeutic Development | $1.34M+7.7% | $1.25M-10.9% | $1.4M+49.7% | $936K-7.8% | $1.02M+9.4% | |
| D&A by Business | ||||||
| Laboratory Services | $23.65M+0.4% | $23.55M-0.2% | $23.59M+0.8% | $23.42M-0.4% | $23.51M-3.0% | |
| Therapeutic Development | $550K-3.7% | $571K-6.4% | $610K-8.8% | $669K-1.3% | $678K-1.5% | |
| Allocated Share Based Compensation Expense by Business | ||||||
| Laboratory Services | $30.68M-2.8% | $31.57M-3.9% | $32.85M-3.9% | $34.19M-3.5% | $35.45M-4.1% | |
| Therapeutic Development | $8.25M+2.9% | $8.02M+1.9% | $7.86M+1.8% | $7.73M-4.2% | $8.07M+7.1% | |
| Finite Lived Intangible Assets Accumulated Amortization by Business | ||||||
| Laboratory Services | $99.25M+7.1% | $92.68M+7.6% | $86.13M+8.2% | $79.62M+8.9% | $73.1M+9.8% | |
| Goodwill by Business | ||||||
| Therapeutic Development | $94.61M+0.3% | $94.36M+3.3% | $91.34M+3.4% | $88.31M+0.1% | $88.27M+0.1% | |
| Revenue by Geography | ||||||
| Non Us | $26.51M+1.5% | $26.12M+9.6% | $23.83M+1.8% | $23.41M-5.0% | $24.65M-3.9% | |
| Other Countries | $13.66M+3.4% | $13.21M+6.5% | $12.41M+0.6% | $12.33M-8.7% | $13.5M+3.8% | |
| PP&E (Net) by Geography | ||||||
| Non Us | $25.41M-1.2% | $25.72M-1.0% | $25.98M+5.6% | $24.59M+8.4% | $22.69M+9.2% | |
| Other Countries | $6.59M-3.0% | $6.8M-4.7% | $7.13M+27.7% | $5.59M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Fulgent Genetics, Inc. break its business down?
- Fulgent Genetics, Inc. (FLGT) reports revenue by business across 2 parts — Laboratory Services and Therapeutic Development. Each is extracted from the segment footnotes and tracked over time.
- Where does Fulgent Genetics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Fulgent Genetics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
